Kringle Pharma Cash Flow Statement

Financials in millions JPY. Fiscal year is October - September.

Millions JPY. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2019
Period Ending	Mar '25 Mar 31, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020	2018 - 2019
Net Income	-900	-754	-852	-330	-299	-116	Upgrade
Other Operating Activities	118	155	147	341	84	96	Upgrade
Change in Accounts Receivable	-	7	-7	6	99	-105	Upgrade
Change in Inventory	113	69	-14	-34	-268	-27	Upgrade
Change in Accounts Payable	13	-135	118	21	-41	27	Upgrade
Change in Other Net Operating Assets	-94	-3	-81	11	-135	-21	Upgrade
Operating Cash Flow	-750	-661	-689	15	-560	-146	Upgrade
Investment in Securities	-131	-121	-120	-254	-	-	Upgrade
Investing Cash Flow	-155	-121	-120	-254	-	-	Upgrade
Issuance of Common Stock	171	838	69	603	612	2,082	Upgrade
Other Financing Activities	-	-	-	-	-17	-	Upgrade
Financing Cash Flow	171	838	69	603	595	2,082	Upgrade
Miscellaneous Cash Flow Adjustments	-	-1	-	-	-1	-	Upgrade
Net Cash Flow	-734	55	-740	364	34	1,936	Upgrade
Cash Income Tax Paid	1	1	1	-6	1	-	Upgrade
Levered Free Cash Flow	-602.88	-552.63	-538.63	-185.25	-505.75	-144.5	Upgrade
Unlevered Free Cash Flow	-602.88	-552.63	-538.63	-185.25	-505.75	-144.5	Upgrade
Change in Net Working Capital	1	42	-17	-81	282	37	Upgrade

Updated Feb 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.